bevacizumab,oxaliplatin,trifluridine tipiracil
roche
[]
members of s gastrointestinal oncology program present phase ii study of tas-ox (tas-102 and oxaliplatin) plus bevacizumab for late-line #colorectal cancer #gi23 
Rutgers Cancer Institute of New Jersey is the state’s only NCI-designated Comprehensive Cancer Center and a leader in patient care and cancer research.